Fresenius and WuXi Biologics form biosimilars deal
In short
The joint initiative brings Fresenius and WuXi Biologics into a collaborative effort to develop and commercialize therapeutic products. By combining development capabilities and manufacturing infrastructure, the partners plan to accelerate the delivery of cost-effective therapies across international territories. This pact provides an operational foundation designed to streamline complex biomanufacturing workflows.
Key points
- The agreement establishes an official framework for the organizations to jointly produce…: The agreement establishes an official framework for the organizations to jointly produce biologic therapies.
- Fresenius continues to expand its commercial footprint through new strategic biopharmaceu…: Fresenius continues to expand its commercial footprint through new strategic biopharmaceutical partnerships worldwide.
- WuXi Biologics will strengthen its presence across the global biosimilar market through t…: WuXi Biologics will strengthen its presence across the global biosimilar market through this newly completed deal.